Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ, Multi-center, Open-label, Single-arm, Dose Escalation, First-in-human Clinical Study of HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

NCT04914351 is registered in ClinicalTrials.gov with Shanghai HyaMab Biotech Co.,Ltd. as lead sponsor.

NCT NCT04914351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04914351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ, Multi-center, Open-label, Single-arm, Dose Escalation, First-in-human Clinical Study of HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
Lead sponsor
Shanghai HyaMab Biotech Co.,Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 3, 2022
Completion date
December 30, 2023
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced/metastatic solid tumors